ARTICLE | Company News
Emergent BioSolutions, HHS infectious news
April 7, 2017 7:43 PM UTC
Emergent signed a modification to its contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) to manufacture and deliver botulism antitoxin heptavalent (BAT) to the U.S. Strategic National Stockpile. The modification is valued at about $53 million over five years. Emergent did not respond to inquiries...
BCIQ Company Profiles